Friday, 16 October 2026European Markets

PAREF And COVIVIO Have A High Dividend Yield And Return On Equity In The REIT—Diversified Industry.

Loading stream...

(vianews) - paref (par.pa) is among this list of stock assets with the highest dividend rate and return on equity on the reit—diversified industry.

financial asset price forward dividend yield return on equity
paref (par.pa) €60.00 7.97% 2.78%
covivio (cov.pa) €49.58 7.56% 8.28%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. paref (par.pa)

7.97% forward dividend yield and 2.78% return on equity

paref sa owns and manages business real estate located primarily in the paris region. the company manages and leases real estate, offices and commercial spaces, and residences. the company also provides real estate agency services. the company was founded in 1997 and is based in paris, france.

earnings per share

as for profitability, paref has a trailing twelve months eps of €2.65.

pe ratio

paref has a trailing twelve months price to earnings ratio of 22.64. meaning, the purchaser of the share is investing €22.64 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.78%.

volume

today's last reported volume for paref is 126 which is 56.7% below its average volume of 291.

more news about paref.

2. covivio (cov.pa)

7.56% forward dividend yield and 8.28% return on equity

thanks to its partnering history, its real estate expertise and its european culture, covivio is inventing today's user experience and designing tomorrow's city. a preferred real estate player at the european level, covivio is close to its end users, capturing their aspirations, combining work, travel, living, and co-inventing vibrant spaces. a benchmark in the european real estate market with €26 bn in assets, covivio offers support to companies, hotel brands and territories in their pursuit for attractiveness, transformation, and responsible performance. build sustainable relationships and well-being, is the covivio's purpose who expresses its role as a responsible real estate operator to all its stakeholders: customers, shareholders and financial partners, internal teams, local authorities but also to future generations and the planet. furthermore, its living, dynamic approach opens up exciting project and career prospects for its teams. covivio's shares are listed in the euronext paris a compartment (fr0000064578 - cov) and on the mta market (mercato telematico azionario) of the milan stock exchange, are admitted to trading on the srd, and are included in the composition of the msci, sbf 120, euronext ieif “siic france” and cac mid100 indices, in the “epra” and “gpr 250” benchmark european real estate indices, epra bprs gold awards (financial + extra-financial), cdp (a-), 5 star gresb and in the esg ftse4 good, cac sbt 1.5°c, djsi world & europe, euronext vigeo (world 120, eurozone 120, europe 120 and france 20), euronext cdp environment france ew, iss esg, ethibel and gaïa ethical indices and also holds the following awards and ratings: cdp (b), gresb (5-star, 100% public disclosure), vigeo-eiris (a1+), iss-esg (b-) and msci (aaa).

earnings per share

as for profitability, covivio has a trailing twelve months eps of €6.64.

pe ratio

covivio has a trailing twelve months price to earnings ratio of 7.47. meaning, the purchaser of the share is investing €7.47 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.28%.

yearly top and bottom value

covivio's stock is valued at €49.58 at 22:40 est, way under its 52-week high of €69.35 and way above its 52-week low of €44.40.

volume

today's last reported volume for covivio is 34490 which is 79.06% below its average volume of 164751.

more news about covivio.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com